25341-42-8

Basic information

• Product Name: Z-3-CYCLOHEXYL-L-ALANINE
• Synonyms: Z-BETA-CYCLOHEXYLALANINE;Z-CHA-OH;Z-3-CYCLOHEXYL-L-ALANINE;Z-L-CYCLOHEXYLALANINE;CBZ-L-CYCLOHEXYLALANINE;(S)-2-(benzyloxycarbonylamino)-3-cyclohexylpropanoic acid;(2S)-[(Benzyloxycarbonyl)amino]-3-cyclohexylpropionic acid;(S)-N-(Benzyloxycarbonyl)cyclohexylalanine
• CAS NO: 25341-42-8
• Molecular Formula: C₁₇H₂₃NO₄
• Molecular Weight: 305.37
• Mol File: 25341-42-8.mol

Chemical Properties

• Boiling Point: 501.4±43.0 °C(Predicted)
• Appearance: /
• Density: 1.167
• Storage Temp.: 2-8°C
• PKA: 4.00±0.10(Predicted)
• CAS DataBase Reference: Z-3-CYCLOHEXYL-L-ALANINE(CAS DataBase Reference)
• NIST Chemistry Reference: Z-3-CYCLOHEXYL-L-ALANINE(25341-42-8)
• EPA Substance Registry System: Z-3-CYCLOHEXYL-L-ALANINE(25341-42-8)

Safety Data

• WGK Germany: 3
• Hazardous Substances Data: 25341-42-8(Hazardous Substances Data)

Usage

Chemical Properties

Transparent, yellow oil

Upstream product

• 163085-09-4 (2S,4S)-4-(cyclohexylmethyl)-2-(1,1-dimethylethyl)-5-oxo-3-oxazolidinecarboxylic acid phenylmethyl ester 
• 163084-89-7 benzyl (2S,4S)-2-(tert-butyl)-4-isobutyl-5-oxooxazolidine-3-carboxylate 
• 4441-50-3 β-cyclohexylalanine 
• 501-53-1 benzyl chloroformate 
• 27527-05-5 L-cyclohexylalanine 
• 17193-39-4 methyl 3-cyclohexyl-L-alaninate hydrochloride 
• 40203-89-2 β-cyclohexyl-L-alanine methyl ester isocyanate 
• 7647-01-0 hydrogenchloride 
• 113828-93-6 (S)-2-Benzyloxycarbonylamino-3-cyclohexyl-propionic acid methyl ester 
• 626-62-0 Cyclohexyl iodide 

Downstream Products

• 118388-23-1 N',O-dimethyl-N-benzyloxycarbonyl-L-cyclohexylalanine hydroxamate 
• 113828-85-6 Cbz-3-cyclohexyl-L-alaninol 
• 211755-74-7 [(S)-1-((S)-2-tert-Butoxy-1-carbamoyl-ethylcarbamoyl)-2-cyclohexyl-ethyl]-carbamic acid benzyl ester 
• 211755-60-1 {(S)-1-[1-((S)-2-Benzyloxycarbonylamino-3-cyclohexyl-propionylamino)-2-hydroxy-ethylcarbamoyl]-2-cyclohexyl-ethyl}-carbamic acid benzyl ester 
• 609367-22-8 ((S)-2-Cyclohexyl-1-dimethylcarbamoyl-ethyl)-carbamic acid benzyl ester 
• 27527-05-5 L-cyclohexylalanine 
• 609367-36-4 2-amino-3-cyclohexyl-N,N-dimethyl-propionamide 
• 609366-97-4 (R)-2-[(Benzyloxy-formyl-amino)-methyl]-hexanoic acid ((S)-2-cyclohexyl-1-dimethylcarbamoyl-ethyl)-amide 
• 1026371-09-4 (S)-2-Amino-N-[1-((S)-2-amino-3-cyclohexyl-propionylamino)-2-hydroxy-ethyl]-3-cyclohexyl-propionamide 
• 105852-47-9 2-<(benzyloxycarbonyl)amino>-3-cyclohexyl-(2S)-propionaldehyde 
• 151337-14-3 tert-butyldimethylsilyl ether of (2S,3S) 2-benzyloxycarbonylamino-1-cyclohexyl-5-isopropyl-5-hexen-3-ol 
• 151337-13-2 (2S,3R) 2-benzyloxycarbonylamino-1-cyclohexyl-5-isopropyl-5-hexen-3-ol 

Relevant articles and documents

Structure-guided design and optimization of dipeptidyl inhibitors of norovirus 3CL protease. Structure-activity relationships and biochemical, X-ray crystallographic, cell-based, and in vivo studies

Norovirus infection constitutes the primary cause of acute viral gastroenteritis. There are currently no vaccines or norovirus-specific antiviral therapeutics available for the management of norovirus infection. Norovirus 3C-like protease is essential for viral replication, consequently, inhibition of this enzyme is a fruitful avenue of investigation that may lead to the emergence of antinorovirus therapeutics. We describe herein the optimization of dipeptidyl inhibitors of norovirus 3C-like protease using iterative SAR, X-ray crystallographic, and enzyme and cell-based studies. We also demonstrate herein in vivo efficacy of an inhibitor using the murine model of norovirus infection.

Potent inhibition of norovirus by dipeptidyl α-hydroxyphosphonate transition state mimics

The design, synthesis, and evaluation of a series of dipeptidyl α-hydroxyphosphonates is reported. The synthesized compounds displayed high anti-norovirus activity in a cell-based replicon system, as well as high enzyme selectivity.

Inhibition of norovirus 3CL protease by bisulfite adducts of transition state inhibitors

Noroviruses are the most common cause of acute viral gastroenteritis, accounting for >21 million cases annually in the US alone. Norovirus infections constitute an important health problem for which there are no specific antiviral therapeutics or vaccines. In this study, a series of bisulfite adducts derived from representative transition state inhibitors (dipeptidyl aldehydes and α-ketoamides) was synthesized and shown to exhibit anti-norovirus activity in a cell-based replicon system. The ED 50 of the most effective inhibitor was 60 nM. This study demonstrates for the first time the utilization of bisulfite adducts of transition state inhibitors in the inhibition of norovirus 3C-like protease in vitro and in a cell-based replicon system. The approach described herein can be extended to the synthesis of the bisulfite adducts of other classes of transition state inhibitors of serine and cysteine proteases, such as α-ketoheterocycles and α-ketoesters.

ACYCLIC 1,3-DIAMINES AND USES THEREFOR

This invention relates to novel compounds useful in the treatment of diseases associated with TRPV4 channel receptor. More specifically, this invention relates to certain substituted -acyclic diamines according to Formula (I): or a pharmaceutically acceptable salt thereof, or a solvate thereof, or a combination thereof, wherein: the R groups are as defined herein. The present invention also relates to a pharmaceutical composition and a method of treatment using the compound of Formula (I).

Practical and efficient enantioselective synthesis of α-amino acids in aqueous media

Enantiomerically pure natural and unnatural α-amino acids have been synthesized from a chiral melhyleneoxazolidinone by means of a highly diastereoselective 1,4-conjugate addition of alkyl iodides in aqueous media. The zinc-copper conjugate addition reaction exhibits high chemoselectivity, with the possibility of using functionalized iodides, to afford a single diastereomer in short reaction times and with good yields.

PEPTIDES RETROVIRAL PROTEASE INHIBITORS COMPRISING 2-AMINO-2-METHYLPROPIONIC ACID

Antiviral peptides of the formula STR1 in which W is an amino protecting group,A,B,D,E and L each independently is a direct bond, or a radical of the formula STR2 R 1 and R 2 each independently is cycloakyl or optionally substituted alkyl or alkenyl,Y is--NHR 10, andR 10 is cycloalkyl or optionally substituted alkyl, and their physiologically acceptable salts.The formula includes a 2-amino-2-methylpropionic acid (AiB) residue, which may optionally be protected, as the N-terminal α-amino acid. The peptides are expected to be useful as medicaments, in particular as antiviral agents in human and veterinary medicine. The peptides are shown to inhibit aspartyl proteases including human immunodeficiency virus (HIV) protease, to have anti-HIV activity and to inhibit the proliferation of HIV in HIV-I infected human lymphocytes. The peptides are expected to be useful in treating patients having HIV related disorders such as ARC and AIDS.